Farxiga granted US BTD in chronic kidney disease
2 October 2020 07:00 BST Farxiga granted Breakthrough Therapy Designation in US for chronic kidney disease Designation follows DAPA-CKD Phase III trial results in which Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease AstraZeneca's Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type-2 diabetes (T2D). CKD is a serious, progressive condition defined by decreased kidney